Nippon India Pharma Fund
Nippon India Mutual Fund · FM: Sailesh Raj Bhan, Kinjal Desai, Amber Singhania · INF204K01I50 · Direct
NAV ₹646.57 AUM ₹9280 Cr as of 22 Sep 2026
Portfolio as of Jul 2026 · Last Update: 16-Aug-2026 05:01 PM IST
Returns
| 1D | 1M | 3M | 6M | 1Y | 3Y | 5Y | Rank (1Y) | TER | |
|---|---|---|---|---|---|---|---|---|---|
| Fund | -0.4% | +0.5% | +4.7% | +17.1% | +12.0% | +19.8% | +13.8% | 50/234 | 0.99% |
Equity allocation
97.32%
Non-equity allocation (combined)
2.68%
All Equity Holdings (35) as of Jul 2026
| # | Company | Value (₹ Cr) | % of AUM | Change |
|---|---|---|---|---|
| 1 | Sun Pharmaceutical Industries Limited | 1235.4 | 13.31% | — |
| 2 | Lupin Limited | 672.3 | 7.25% | — |
| 3 | Divi's Laboratories Limited | 604.8 | 6.52% | — |
| 4 | Cipla Limited | 559.1 | 6.03% | — |
| 5 | Apollo Hospitals Enterprise Limited | 491.6 | 5.30% | — |
| 6 | Dr. Reddy's Laboratories Limited | 464.9 | 5.01% | — |
| 7 | Mankind Pharma Limited | 346.8 | 3.74% | — |
| 8 | Sai Life Sciences Limited | 336.1 | 3.62% | — |
| 9 | Ajanta Pharma Limited | 316.7 | 3.41% | — |
| 10 | Max Healthcare Institute Limited | 292.0 | 3.15% | — |
| 11 | MedPlus Health Services Limited | 249.9 | 2.69% | — |
| 12 | GlaxoSmithKline Pharmaceuticals Limited | 246.6 | 2.66% | — |
| 13 | IPCA Laboratories Limited | 238.5 | 2.57% | — |
| 14 | Thyrocare Technologies Limited | 232.6 | 2.51% | — |
| 15 | Vijaya Diagnostic Centre Limited | 224.7 | 2.42% | — |
| 16 | Abbott India Limited | 207.9 | 2.24% | — |
| 17 | Gland Pharma Limited | 200.4 | 2.16% | — |
| 18 | Piramal Pharma Limited | 194.4 | 2.09% | — |
| 19 | Dr. Lal Path Labs Limited | 190.6 | 2.05% | — |
| 20 | Alkem Laboratories Limited | 186.2 | 2.01% | — |
| 21 | Narayana Hrudayalaya Limited | 167.2 | 1.80% | — |
| 22 | Pfizer Limited | 153.5 | 1.65% | — |
| 23 | Emcure Pharmaceuticals Limited | 146.3 | 1.58% | — |
| 24 | Aurobindo Pharma Limited | 142.6 | 1.54% | — |
| 25 | Syngene International Limited | 135.1 | 1.46% | — |
| 26 | Fortis Healthcare Limited | 127.2 | 1.37% | — |
| 27 | Sanofi India Limited | 99.6 | 1.07% | — |
| 28 | Sanofi Consumer Healthcare India Limited | 98.5 | 1.06% | — |
| 29 | Suraksha Diagnostic Limited | 98.2 | 1.06% | — |
| 30 | Akums Drugs and Pharmaceuticals Limited | 92.5 | 1.00% | — |
| 31 | Anthem Biosciences Limited | 85.7 | 0.92% | — |
| 32 | Biocon Limited | 85.3 | 0.92% | — |
| 33 | AstraZeneca Pharma India Limited | 50.7 | 0.55% | — |
| 34 | Indoco Remedies Limited | 40.3 | 0.43% | — |
| 35 | Concord Biotech Limited | 15.9 | 0.17% | — |
All disclosed equity positions are shown. Non-equity allocation is the remaining portfolio weight after disclosed equities.